No Data
No Data
BioCardia Secures New Patent For Innovative Heart Procedure Technology
BioCardia, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Unites States Patent
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces
CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III
CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial injection of ProtheraCytes for acute myocardial infarction when delivered in com
Express News | BioCardia Inc - Protheracytes Well Tolerated in Phase I/Iib Trial
Express News | BioCardia Inc - Cellprothera, Co Plan Phase III Trial
Express News | Cellprothera and BioCardia Collaborate on Successful Phase II Trial of Protheracytes™ for the Treatment of Acute Myocardial Infarction
No Data